Browsing tag:

Bipolar Disorder


Alkermes excitedly announced extremely positive study data from a Phase 3 trial of Aripiprazole. This randomized, placebo-controlled and double-blind study gleaned better than expected results, leading pharmaceutical executives at Alkermes to set a plan in motion for an NDA by the third quarter of 2014. As a long acting and injectable antipsychotic treatment Aripiprazole Lauroxil[…]

Read More

As a blockbuster medication used to treat schizophrenia, Aripiprazole CAS# 129722-12-9 has recently been approved by the FDA as a once a month treatment. Marketed by Otsuka and Bristol-Myers Squibb, this monthly dosage of aripiprazole will be sold under the name Abilify Maintena. Aripiprazole is a solid and reliable long-acting antipsychotic medication, and this FDA[…]

Read More

Asenapine, also known as Saphris, marketed by Merck, is an efficacious drug for patients suffering from schizophrenia and bipolar disorder. Classified as an antipsychotic medication, Asenapine, CAS# 65576-45-6 is available in sublingual tablets of 5 and 10 milligrams. With the patent of Saphris expiring on June 8, 2015, a generic form of this lifesaving drug[…]

Read More

Risperidone is sold under the brand name Risperdal in the United States. First developed by Janssen-Cilag, risperidone is an atypical antipsychotic that was initially released in 1994. Risperdal (risperidone) is used for patients suffering from adolescent and adult schizophrenia, schizoaffective disorder, and manic states of bipolar disorder. The FDA approved risperidone in 2003 for short[…]

Read More